188 related articles for article (PubMed ID: 20370655)
1. Pharmacophoric models and 3D QSAR studies of the adenosine receptor ligands.
Tintori C; Manetti F; Botta M
Curr Top Med Chem; 2010; 10(10):1019-35. PubMed ID: 20370655
[TBL] [Abstract][Full Text] [Related]
2. Quantitative structure activity relationships as useful tools for the design of new adenosine receptor ligands. 1. Agonist.
González MP; Terán C; Teijeira M; Helguera AM
Curr Med Chem; 2006; 13(19):2253-66. PubMed ID: 16918353
[TBL] [Abstract][Full Text] [Related]
3. Optimization of adenosine 5'-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening.
Tosh DK; Phan K; Gao ZG; Gakh AA; Xu F; Deflorian F; Abagyan R; Stevens RC; Jacobson KA; Katritch V
J Med Chem; 2012 May; 55(9):4297-308. PubMed ID: 22486652
[TBL] [Abstract][Full Text] [Related]
4. Search for new antagonist ligands for adenosine receptors from QSAR point of view. How close are we?
González MP; Terán C; Teijeira M
Med Res Rev; 2008 May; 28(3):329-71. PubMed ID: 17668454
[TBL] [Abstract][Full Text] [Related]
5. Medicinal chemistry of adenosine, P2Y and P2X receptors.
Jacobson KA; Müller CE
Neuropharmacology; 2016 May; 104():31-49. PubMed ID: 26686393
[TBL] [Abstract][Full Text] [Related]
6. Adenosine receptor ligands-recent developments part I. Agonists.
Muller CE
Curr Med Chem; 2000 Dec; 7(12):1269-88. PubMed ID: 11032971
[TBL] [Abstract][Full Text] [Related]
7. G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactions.
Jacobson KA; Balasubramanian R; Deflorian F; Gao ZG
Purinergic Signal; 2012 Sep; 8(3):419-36. PubMed ID: 22371149
[TBL] [Abstract][Full Text] [Related]
8. Structural Mapping of Adenosine Receptor Mutations: Ligand Binding and Signaling Mechanisms.
Jespers W; Schiedel AC; Heitman LH; Cooke RM; Kleene L; van Westen GJP; Gloriam DE; Müller CE; Sotelo E; Gutiérrez-de-Terán H
Trends Pharmacol Sci; 2018 Jan; 39(1):75-89. PubMed ID: 29203139
[TBL] [Abstract][Full Text] [Related]
9. Recent Advances of In-Silico Modeling of Potent Antagonists for the Adenosine Receptors.
Samanta PN; Kar S; Leszczynski J
Curr Pharm Des; 2019; 25(7):750-773. PubMed ID: 30836910
[TBL] [Abstract][Full Text] [Related]
10. Alternative quality assessment strategy to compare performances of GPCR-ligand docking protocols: the human adenosine A(2A) receptor as a case study.
Ciancetta A; Cuzzolin A; Moro S
J Chem Inf Model; 2014 Aug; 54(8):2243-54. PubMed ID: 25046649
[TBL] [Abstract][Full Text] [Related]
11. Structure-Based Rational Design of Adenosine Receptor Ligands.
Gutiérrez-de-Terán H; Sallander J; Sotelo E
Curr Top Med Chem; 2017; 17(1):40-58. PubMed ID: 27448653
[TBL] [Abstract][Full Text] [Related]
12. Structure based prediction of subtype-selectivity for adenosine receptor antagonists.
Katritch V; Kufareva I; Abagyan R
Neuropharmacology; 2011 Jan; 60(1):108-15. PubMed ID: 20637786
[TBL] [Abstract][Full Text] [Related]
13. Linear and nonlinear 3D-QSAR approaches in tandem with ligand-based homology modeling as a computational strategy to depict the pyrazolo-triazolo-pyrimidine antagonists binding site of the human adenosine A2A receptor.
Michielan L; Bacilieri M; Schiesaro A; Bolcato C; Pastorin G; Spalluto G; Cacciari B; Klotz KN; Kaseda C; Moro S
J Chem Inf Model; 2008 Feb; 48(2):350-63. PubMed ID: 18215030
[TBL] [Abstract][Full Text] [Related]
14. Fluorescent ligands for adenosine receptors.
Kozma E; Jayasekara PS; Squarcialupi L; Paoletta S; Moro S; Federico S; Spalluto G; Jacobson KA
Bioorg Med Chem Lett; 2013 Jan; 23(1):26-36. PubMed ID: 23200243
[TBL] [Abstract][Full Text] [Related]
15. Limits of ligand selectivity from docking to models: in silico screening for A(1) adenosine receptor antagonists.
Kolb P; Phan K; Gao ZG; Marko AC; Sali A; Jacobson KA
PLoS One; 2012; 7(11):e49910. PubMed ID: 23185482
[TBL] [Abstract][Full Text] [Related]
16. Molecular Dynamics Simulations of Adenosine Receptors: Advances, Applications and Trends.
Al-Shar'i NA; Al-Balas QA
Curr Pharm Des; 2019; 25(7):783-816. PubMed ID: 30834825
[TBL] [Abstract][Full Text] [Related]
17. Allosteric modulators for adenosine receptors: an alternative to the orthosteric ligands.
La Motta C; Sartini S; Morelli M; Taliani S; Da Settimo F
Curr Top Med Chem; 2010; 10(10):976-92. PubMed ID: 20370657
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Novel Adenosine Receptor Antagonists through a Combined Structure- and Ligand-Based Approach Followed by Molecular Dynamics Investigation of Ligand Binding Mode.
Lagarias P; Vrontaki E; Lambrinidis G; Stamatis D; Convertino M; Ortore G; Mavromoustakos T; Klotz KN; Kolocouris A
J Chem Inf Model; 2018 Apr; 58(4):794-815. PubMed ID: 29485875
[TBL] [Abstract][Full Text] [Related]
19. Functionalized congener approach to the design of ligands for G protein-coupled receptors (GPCRs).
Jacobson KA
Bioconjug Chem; 2009 Oct; 20(10):1816-35. PubMed ID: 19405524
[TBL] [Abstract][Full Text] [Related]
20. QSAR modeling of GPCR ligands: methodologies and examples of applications.
Tropsha A; Wang SX
Ernst Schering Found Symp Proc; 2006; (2):49-73. PubMed ID: 17703577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
